Alar Pharmaceuticals Inc. (TPEX:6785)
Taiwan · Delayed Price · Currency is TWD 123.00
+0.50 (0.41%)
May 29, 2026, 1:30 PM CST
Alar Pharmaceuticals Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3 | 2.75 | 5.82 | 469.27 | 0.8 | - | |
Revenue Growth (YoY) | -48.38% | -52.67% | -98.76% | 58559.00% | - | - |
Cost of Revenue | 0.61 | 0.61 | 2.03 | - | - | - |
Gross Profit | 2.39 | 2.14 | 3.79 | 469.27 | 0.8 | - |
Selling, General & Admin | 12.45 | 13.43 | 14.39 | 27.03 | 13.15 | 11.41 |
Research & Development | 178.85 | 156.51 | 57.34 | 56.71 | 34.18 | 81.89 |
Operating Expenses | 191.3 | 169.94 | 71.73 | 83.75 | 47.33 | 93.3 |
Operating Income | -188.91 | -167.8 | -67.94 | 385.53 | -46.53 | -93.3 |
Interest Expense | -0.08 | -0.08 | -0.03 | -0.06 | -0.02 | -0.02 |
Interest & Investment Income | 52.05 | 54.52 | 66.31 | 16.92 | 2.79 | 1.5 |
Earnings From Equity Investments | - | -0.75 | -8.54 | - | - | - |
Currency Exchange Gain (Loss) | 24.7 | 24.7 | 46.72 | -11.32 | 1.67 | 0.07 |
Other Non Operating Income (Expenses) | -3.4 | 0.64 | 0.53 | 0.04 | 9.55 | 27.52 |
EBT Excluding Unusual Items | -115.64 | -88.75 | 37.05 | 391.11 | -32.54 | -64.23 |
Gain (Loss) on Sale of Investments | 9.78 | 9.78 | - | - | - | - |
Pretax Income | -105.86 | -78.97 | 37.05 | 391.11 | -32.54 | -64.23 |
Income Tax Expense | 6.91 | 0.71 | 18.88 | 8.49 | -12.67 | - |
Net Income | -112.77 | -79.68 | 18.17 | 382.62 | -19.87 | -64.23 |
Net Income to Common | -112.77 | -79.68 | 18.17 | 382.62 | -19.87 | -64.23 |
Net Income Growth | - | - | -95.25% | - | - | - |
Shares Outstanding (Basic) | 67 | 67 | 66 | 57 | 57 | 57 |
Shares Outstanding (Diluted) | 67 | 67 | 66 | 57 | 57 | 57 |
Shares Change (YoY) | -0.02% | 0.87% | 16.08% | 0.09% | - | 14.21% |
EPS (Basic) | -1.69 | -1.19 | 0.27 | 6.71 | -0.35 | -1.13 |
EPS (Diluted) | -1.69 | -1.19 | 0.27 | 6.71 | -0.35 | -1.13 |
EPS Growth | - | - | -95.98% | - | - | - |
Free Cash Flow | -156.13 | -173.9 | -107.44 | 397.23 | -34.09 | -65.05 |
Free Cash Flow Per Share | -2.34 | -2.60 | -1.62 | 6.96 | -0.60 | -1.14 |
Dividend Per Share | 0.100 | 0.100 | 0.250 | 1.500 | - | - |
Dividend Growth | -60.00% | -60.00% | -83.33% | - | - | - |
Gross Margin | 79.59% | 77.73% | 65.15% | 100.00% | 100.00% | - |
Operating Margin | -6290.64% | -6095.10% | -1168.02% | 82.15% | -5815.88% | - |
Profit Margin | -3755.24% | -2894.41% | 312.36% | 81.53% | -2483.88% | - |
Free Cash Flow Margin | -5199.10% | -6316.67% | -1846.95% | 84.65% | -4260.75% | - |
EBITDA | -185.8 | -165.35 | -65.43 | 387.58 | -44.16 | -90.82 |
EBITDA Margin | - | - | - | 82.59% | - | - |
D&A For EBITDA | 3.11 | 2.45 | 2.51 | 2.05 | 2.36 | 2.48 |
EBIT | -188.91 | -167.8 | -67.94 | 385.53 | -46.53 | -93.3 |
EBIT Margin | - | - | - | 82.15% | - | - |
Effective Tax Rate | - | - | 50.96% | 2.17% | - | - |